TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Item
http://www.wikidata.org/entity/Q33429430
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesTAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.Inhibiting 4EBP1 in glioblastoma.m-TOR inhibitors and their potential role in haematological malignancies.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets.The PI3K Pathway in Human Disease.CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro.PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.Biological Aspects of mTOR in Leukemia
P2860

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Item
http://www.wikidata.org/entity/Q33429430
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
type
label
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
prefLabel
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@ast
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
TAK-228 (formerly MLN0128), an ...... ldenström's macroglobulinemia.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698